Edition:
United States

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

85.35EUR
11:35am EDT
Change (% chg)

€-0.35 (-0.41%)
Prev Close
€85.70
Open
€86.00
Day's High
€86.20
Day's Low
€83.40
Volume
133,918
Avg. Vol
160,529
52-wk High
€124.90
52-wk Low
€70.55

Select another date:

Thu, Jul 19 2018

Photo

Novartis to pay 95 million euros to Galapagos, MorphoSys for skin drug

ZURICH Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug

ZURICH, July 19 Novartis said on Thursday it will pay 95 million euros ($110.49 million) to Galapagos and MorphoSys to license a prospective medicine targeting the skin condition atopic dermatitis, as the Swiss drugmaker strengthens its foothold in immunology.

BRIEF-Morphosys AG Reports Q1 Revenue Of 2.8 Million EUR

* Q1 REVENUE 2.8 MILLION EUR VERSUS 11.8 MILLION EUR YEAR AGO

BRIEF-Morphosys, Galapagos initiate IGUANA phase 2 clinical trial with Mor106 in Atopic Dermatitis patients

* DGAP-NEWS: MORPHOSYS AND GALAPAGOS ANNOUNCE INITIATION OF THE IGUANA PHASE 2 CLINICAL TRIAL WITH MOR106 IN ATOPIC DERMATITIS PATIENTS

BRIEF-MorphoSys Announces Approval Of Tremfya(R)In South Korea

* DGAP-NEWS: MORPHOSYS ANNOUNCES APPROVAL OF TREMFYA(R) (GUSELKUMAB) IN SOUTH KOREA

BRIEF-Morphosys Says NASDAQ IPO Leads To Total Gross Proceeds Of USD 239 Million

* DGAP-NEWS: MORPHOSYS ANNOUNCES CLOSING OF NASDAQ IPO THROUGH AN ADS OFFERING AND EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL ADSS, LEADING TO TOTAL GROSS PROCEEDS OF USD 239 MILLION

Select another date: